Rhumbline Advisers boosted its position in Pacira Pharmaceuticals Inc (NASDAQ:PCRX) by 3.5% during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 39,897 shares of the company’s stock after acquiring an additional 1,335 shares during the period. Rhumbline Advisers owned 0.10% of Pacira Pharmaceuticals worth $1,279,000 as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in the business. venBio Select Advisor LLC lifted its holdings in shares of Pacira Pharmaceuticals by 102.1% in the first quarter. venBio Select Advisor LLC now owns 1,715,072 shares of the company’s stock valued at $53,424,000 after purchasing an additional 866,500 shares in the last quarter. PointState Capital LP lifted its holdings in shares of Pacira Pharmaceuticals by 71.1% in the first quarter. PointState Capital LP now owns 2,038,153 shares of the company’s stock valued at $63,488,000 after purchasing an additional 847,146 shares in the last quarter. Nexthera Capital LP bought a new position in shares of Pacira Pharmaceuticals in the first quarter valued at approximately $14,909,000. Summit Trail Advisors LLC lifted its holdings in shares of Pacira Pharmaceuticals by 2,888.3% in the first quarter. Summit Trail Advisors LLC now owns 399,688 shares of the company’s stock valued at $400,000 after purchasing an additional 386,313 shares in the last quarter. Finally, Millennium Management LLC lifted its holdings in shares of Pacira Pharmaceuticals by 64.6% in the first quarter. Millennium Management LLC now owns 888,391 shares of the company’s stock valued at $27,673,000 after purchasing an additional 348,542 shares in the last quarter.

Shares of Pacira Pharmaceuticals stock opened at $46.55 on Monday. The firm has a market cap of $1.90 billion, a P/E ratio of -80.26 and a beta of 1.99. Pacira Pharmaceuticals Inc has a 12 month low of $26.95 and a 12 month high of $48.40. The company has a debt-to-equity ratio of 0.98, a quick ratio of 7.79 and a current ratio of 8.58.

Pacira Pharmaceuticals (NASDAQ:PCRX) last issued its quarterly earnings results on Thursday, August 2nd. The company reported $0.24 EPS for the quarter, topping the Zacks’ consensus estimate of ($0.13) by $0.37. Pacira Pharmaceuticals had a negative return on equity of 0.39% and a negative net margin of 3.64%. The business had revenue of $84.10 million for the quarter, compared to analyst estimates of $77.53 million. During the same period last year, the company posted ($0.11) earnings per share. Pacira Pharmaceuticals’s quarterly revenue was up 18.6% compared to the same quarter last year. research analysts anticipate that Pacira Pharmaceuticals Inc will post -0.18 EPS for the current year.

In other Pacira Pharmaceuticals news, VP Lauren Bullaro Riker sold 1,667 shares of the firm’s stock in a transaction on Wednesday, August 22nd. The stock was sold at an average price of $44.48, for a total value of $74,148.16. Following the completion of the sale, the vice president now directly owns 10,474 shares of the company’s stock, valued at $465,883.52. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Mark A. Kronenfeld bought 1,000 shares of the firm’s stock in a transaction on Tuesday, August 28th. The stock was purchased at an average cost of $44.61 per share, with a total value of $44,610.00. Following the completion of the transaction, the director now directly owns 8,577 shares of the company’s stock, valued at $382,619.97. The disclosure for this purchase can be found here. Insiders sold 39,502 shares of company stock valued at $1,863,164 over the last three months. Company insiders own 5.90% of the company’s stock.

PCRX has been the topic of a number of recent research reports. HC Wainwright restated a “buy” rating and issued a $48.00 target price on shares of Pacira Pharmaceuticals in a report on Tuesday, July 10th. ValuEngine upgraded Pacira Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Saturday, July 28th. Royal Bank of Canada set a $50.00 target price on Pacira Pharmaceuticals and gave the company a “buy” rating in a report on Thursday, August 2nd. Piper Jaffray Companies set a $48.00 target price on Pacira Pharmaceuticals and gave the company a “buy” rating in a report on Thursday, August 2nd. Finally, Needham & Company LLC upgraded Pacira Pharmaceuticals from a “hold” rating to a “buy” rating and set a $54.00 price target on the stock in a report on Friday, August 3rd. Three analysts have rated the stock with a sell rating, eleven have assigned a hold rating and nine have given a buy rating to the stock. Pacira Pharmaceuticals currently has an average rating of “Hold” and a consensus price target of $46.84.

About Pacira Pharmaceuticals

Pacira Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, and commercializes proprietary pharmaceutical products primarily for use in hospitals and ambulatory surgery centers in the United States. It develops pharmaceutical products based on its proprietary DepoFoam drug delivery technology.

Read More: How Important is Technical Analysis of Stocks

Want to see what other hedge funds are holding PCRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pacira Pharmaceuticals Inc (NASDAQ:PCRX).

Institutional Ownership by Quarter for Pacira Pharmaceuticals (NASDAQ:PCRX)

Receive News & Ratings for Pacira Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.